TCRT
Live chart
What they do
Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations.
For information only · Important disclosures
Grades vs sector
No sector grades for TCRT yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Our models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Discounted cash flow
Edit assumptions · recalculates instantly
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta -0.87 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs sector
Forward EPS $-0.60 vs trailing $-1.76. Forward P/E uses analysts' next-12-month estimate.
Backlog (remaining performance obligations)
Contracted revenue not yet recognized, from SEC filings (XBRL tag RevenueRemainingPerformanceObligation).
Quality & financial health
Piotroski F-score 3/9 · last two fiscal years
Altman Z-score -858.6 (distress zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $5.0K | $-4.2M | $-3.0M |
| 2024 | $10.0K | $-4.7M | $-5.0M |
| 2023 | $5.0K | $-4.7M | $-30.3M |
| 2022 | $2.9M | $-37.7M | $-29.4M |
| 2021 | $398.0K | $-78.8M | $-64.8M |
| 2020 | $0 | $-80.0M | $-66.8M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR -88.0%.
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2024-04-01 | -4.50 | -17.09 | -279.9% |
| 2023-11-14 | -5.25 | -4.41 | +16.0% |
| 2023-08-14 | -6.75 | -6.00 | +11.1% |
| 2023-05-10 | -6.60 | -6.00 | +9.1% |
| 2023-03-07 | -10.00 | -6.00 | +40.0% |
| 2022-11-14 | -10.75 | -6.00 | +44.2% |
| 2022-08-15 | -10.25 | -7.50 | +26.8% |
| 2022-05-16 | -9.90 | -7.50 | +24.2% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $0 | – |
| 2026-03-31 | $0 | – |
| 2025-12-31 | $3.0K | – |
| 2025-09-30 | $0 | – |
| 2025-06-30 | $0 | – |
Stats refreshed 2026-10-21 01:31:19 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app
Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.
Beta 0.9 · Oct 21, 2026